In conclusion, here we show that the sialyltransferase enzyme ST6GAL1 is upregulated in tumours and blood samples from patients with prostate cancer bone metastasis and that ST6GAL1-mediated aberrant sialylation can promote the spread of prostate tumours to bone. Here, ST6GAL1 is linked to prostate carcinoma.